Roles of eosinophils in the modulation of angiogenesis

Chemical Immunology and Allergy

Volumn 99, Issue , 2014, Pages 138-154

  Efraim, Alon H Nissim Ben ^a   Levi Schaffer, Francesca ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD300A; PROTEIN; UNCLASSIFIED DRUG; CD300A PROTEIN, HUMAN; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC DISEASE; ANGIOGENESIS; APOPTOSIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CELL DEATH; CELL VIABILITY; CHRONIC DISEASE; CHRONIC INFLAMMATION; CHRONIC RHINOSINUSITIS; EOSINOPHIL; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; HYPOXEMIA; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; NONHUMAN; NOSE POLYP; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL; TISSUE INJURY; VASCULARIZATION; WHEEZING; ANIMAL; ANOXIA; CELL MOTION; CYTOLOGY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HYPERSENSITIVITY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; ANTIGENS, CD; CELL MOVEMENT; CYTOKINES; ENDOTHELIAL CELLS; EOSINOPHILS; GENE EXPRESSION REGULATION; HUMANS; HYPERSENSITIVITY; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904226645     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000353251     Document Type: Article

References (124)

1. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol. 2002; 2: 787-795
2. Holgate ST, Church M, Lichtenstein LM. Allergy. Philadelphia, Mosby Elsevier, 2006
3. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008; 454: 445-454
4. Bochner BS, Busse WW. Allergy and asthma. J Allergy Clin Immunol. 2005; 115: 953-959
5. Jeffery PK, Haahtela T. Allergic rhinitis and asthma: inflammation in a one-Airway condition. BMC Pulm Med. 2006; 6(suppl 1): S5
6. Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009; 123: 1004-1011
7. Elishmereni M, Alenius HT, Bradding P, Mizrahi S, Shikotra A, Minai-Fleminger Y, Mankuta D, Eliashar R, Zabucchi G, Levi-Schaffer F. Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro. Allergy. 2011; 66: 376-385
8. Minai-Fleminger Y, Elishmereni M, Vita F, Soranzo MR, Mankuta D, Zabucchi G, and Levi-Schaffer F. Ultrastructural evidence for human mast cell-eosinophil interactions in vitro. Cell Tissue Res. 2010; 341: 405-415
9. Hartman M, Piliponsky AM, Temkin V, Levi-Schaffer F. Human peripheral blood eosinophils express stem cell factor. Blood. 2001; 97: 1086-1091
10. Columbo M, Horowitz EM, Botana LM, MacGlashan DW Jr, Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol. 1992; 149: 599-608
11. Solomon A, Aloe L, Pe'er J, Frucht-Pery J, Bonini S, and Levi-Schaffer F. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol. 1998; 102: 454-460
12. Micera A, Puxeddu I, Aloe L, Levi-Schaffer F. New insights on the involvement of Nerve Growth Factor in allergic inflammation and fibrosis. Cytokine Growth Factor Rev. 2003; 14: 369-374
13. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res. 2003; 24: 271-281
14. Elishmereni M, Bachelet I, Ben-Efraim AH, Mankuta D, Levi-Schaffer F. Interacting mast cells and eosinophils acquire an enhanced activation state in vitro. Allergy, 2012
15. Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol. 1960; 13: 27-33
16. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, Bonsignore G. Airway remodeling in asthma. CheSt 2003; 123: 417S-422S.
17. James A. Airway remodeling in asthma. Curr Opin Pulm Med. 2005; 11: 1-6
18. Gleich GJ. Mechanisms of eosinophil-Associated inflammation. J Allergy Clin Immunol. 2000; 105: 651-663
19. White SR, Ohno S, Munoz NM, Gleich GJ, Abrahams C, Solway J, Leff AR. Epithelium-dependent contraction of airway smooth muscle caused by eosinophil MBP. Am J Physiol. 1990; 259: L294-L303
20. Bandeira-Melo C, Bozza PT, Weller PF. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol. 2002; 109: 393-400
21. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol. 2004; 22: 789-815
22. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med. 2001; 164: S39-S45
23. Chetta A, Zanini A, Foresi A, D'Ippolito R, Tipa A, Castagnaro A, Baraldo S, Neri M, Saetta M, Olivieri D. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy. 2005; 35: 1437-1442
24. Salvato G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-Asthmatic subjects. Thorax. 2001; 56: 902-906
25. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med. 1997; 156: 229-233
26. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001; 107: 295-301
27. Asai K, Kanazawa H, Otani K, Shiraishi S, Hirata K, and Yoshikawa J. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J Allergy Clin Immunol. 2002; 110: 571-575
28. Simcock DE, Kanabar V, Clarke GW, O'Connor BJ, Lee TH, Hirst SJ. Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma. Am J Respir Crit Care Med. 2007; 176: 146-153
29. Eliashar R, Levi-Schaffer F. The role of the eosinophil in nasal diseases. Curr Opin Otolaryngol Head Neck Surg. 2005; 13: 171-175
30. Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y. Mast cells in atopic dermatitis. Curr Opin Immunol. 2009; 21: 666-678
31. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004; 59: 561-570
32. Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol. 1995; 96: 302-318; quiz 319
33. Levi-Schaffer F, Garbuzenko E, Rubin A, Reich R, Pickholz D, Gillery P, Emonard H, Nagler A, Maquart FA. Human eosinophils regulate human lung-And skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci USA. 1999; 96: 9660-9665
34. Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q. Eosinophil-Associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol. 1997; 17: 326-333
35. Fattouh R, Jordana M. TGF-beta, eosinophils and IL-13 in allergic airway remodeling: a critical appraisal with therapeutic considerations. Inflamm Allergy Drug Targets. 2008; 7: 224-236
36. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin InveSt 2003; 112: 1029-1036
37. Uings I, Puxeddu I, Temkin V, Smith SJ, Fattah D, Ray KP, Levi-Schaffer F. Effects of dexamethasone on TNF-Alpha-induced release of cytokines from purified human blood eosinophils. Clin Mol Allergy. 2005; 3: 5
38. Ehrlich P. Farbenanalytische Untersuchungen zur Histologie und Klinik des Blutes. K. University, ed. Berlin, August Hirschwald, 1891
39. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006; 24: 147-174
40. Weller PF. Human eosinophils. J Allergy Clin Immunol. 1997; 100: 283-287
41. Resnick MB, Weller PF. Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol. 1993; 8: 349-355
42. Yao T, Kojima Y, Koyanagi A, Yokoi H, Saito T, Kawano K, Furukawa M, Kusunoki T, Ikeda K. Eotaxin-1, -2, and -3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients. Laryngoscope. 2009; 119: 1053-1059
43. Owczarek W, Paplinska M, Targowski T, Jahnz-Rozyk K, Paluchowska E, Kucharczyk A, Kasztalewicz B. Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis. Cytokine. 2010; 50: 181-185
44. Komiya A, Nagase H, Yamada H, Sekiya T, Yamaguchi M, Sano Y, Hanai N, Furuya A, Ohta K, Matsushima K, Yoshie O, Yamamoto K, Hirai K. Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. Cell Immunol. 2003; 225: 91-100
45. Lamkhioued B, Abdelilah SG, Hamid Q, Mansour N, Delespesse G, Renzi PM. The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells. J Immunol. 2003; 170: 537-547
46. Rothenberg ME. Eosinophilia. N Engl J Med. 1998; 338: 1592-1600
47. Melo RC, Weller PF, Dvorak AM. Activated human eosinophils. Int Arch Allergy Immunol. 2005; 138: 347-349
48. Yousefi S, Blaser K, Simon HU. Activation of signaling pathways and prevention of apoptosis by cytokines in eosinophils. Int Arch Allergy Immunol. 1997; 112: 9-12
49. Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K, Zangemeister-Wittke U, Akbar AN, Simon HU. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood. 1998; 92: 778-783
50. Her E, Frazer J, Austen KF, Owen WF Jr. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin InveSt 1991; 88: 1982-1987
51. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood. 1991; 78: 2542-2547
52. Melo RC, Perez SA, Spencer LA, Dvorak AM, and Weller PF. Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. Traffic. 2005; 6: 866-879
53. Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, Mahmudi-Azer S, Odemuyiwa SO, Dvorak AM, Moqbel R, Weller PF. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci USA. 2008; 105: 18478-18483
54. Slifman NR, Loegering DA, McKean DJ, Gleich GJ. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol. 1986; 137: 2913-2917
55. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulson A. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999; 29: 1172-1186
56. Piliponsky AM, Pickholtz D, Gleich GJ, Levi-Schaffer F. Human eosinophils induce histamine release from antigen-Activated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic reactions. J Allergy Clin Immunol. 2001; 107: 993-1000
57. MacPherson JC, Comhair SA, Erzurum SC, Klein DF, Lipscomb MF, Kavuru MS, Samoszuk MK, Hazen SL. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol. 2001; 166: 5763-5772
58. Plager DA, Loegering DA, Checkel JL, Tang J, Kephart GM, Caffes PL, Adolphson CR, Ohnuki LE, Gleich GJ. Major basic protein homolog (MBP2): a specific human eosinophil marker. J Immunol. 2006; 177: 7340-7345
59. Kay AB, Phipps S, Robinson DS A role for eosinophils in airway remodelling in asthma. Trends Immunol. 2004; 25: 477-482
60. Holgate ST Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine. 2004; 28: 152-157
61. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, Ghiran S, Gerard NP, Yu C, Orkin SH, Gerard C A critical role for eosinophils in allergic airways remodeling. Science. 2004; 305: 1776-1779
62. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Friedman S, Broide DH. Inhibition of airway remodeling in IL-5-deficient mice. J Clin InveSt 2004; 113: 551-560
63. Munitz A, Bachelet I, Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol. 2006; 118: 1082-1089
64. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol. 1997; 17: 70-77
65. Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F. Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol. 2005; 37: 628-636
66. Yousefi S, Hemmann S, Weber M, Holzer C, Hartung K, Blaser K, Simon HU. IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma. J Immunol. 1995; 154: 5481-5490
67. Salcedo R, Young HA, Ponce ML, Ward JM, Kleinman HK, Murphy WJ, Oppenheim JJ. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol. 2001; 166: 7571-7578
68. Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC, Mantovani A. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin InveSt 1991; 87: 986-995
69. Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ, Aglietta M, Arese P, Mantovani A. Granulocyte-And granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature. 1989; 337: 471-473
70. Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol. 2005; 116: 531-536
71. Puxeddu I, Berkman N, Nissim Ben Efraim AH, Davies DE, Ribatti D, Gleich GJ, and Levi-Schaffer F. The role of eosinophil major basic protein in angiogenesis. Allergy. 2009; 64: 368-374
72. O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 2003; 14: 479-488
73. Kohan M, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Enhanced osteopontin expression in a murine model of allergen-induced airway remodelling. Clin Exp Allergy. 2007; 37: 1444-1454
74. Kohan M, Breuer R, Berkman N. Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am J Respir Cell Mol Biol. 2009; 41: 290-296
75. Puxeddu I, Berkman N, Ribatti D, Bader R, Haitchi HM, Davies DE, Howarth PH, Levi-Schaffer F. Osteopontin is expressed and functional in human eosinophils. Allergy. 2010; 65: 168-174
76. Fujisawa T, Kato Y, Terada A, Iguchi K, Kamiya H. Matrix metalloproteinase-9 in peripheral blood eosinophils. Int Arch Allergy Immunol. 1999; 120(suppl 1): 65-69
77. Temkin V, Aingorn H, Puxeddu I, Goldshmidt O, Zcharia E, Gleich GJ, Vlodavsky I, and Levi-Schaffer F. Eosinophil major basic protein: first identified natural heparanase-inhibiting protein. J Allergy Clin Immunol. 2004; 113: 703-709
78. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol. 1997; 17: 519-528
79. Schwingshackl A, Duszyk M, Brown N, Moqbel R. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-Alpha. J Allergy Clin Immunol. 1999; 104: 983-989
80. Saadi S, Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J 2002; 16: 849-856
81. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle. 2005; 4: 256-258
82. Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell. 1997; 89: 9-12
83. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W. Review: hypoxia-inducible factor-1 (HIF-1) A novel transcription factor in immune reactions. J Interferon Cytokine Res. 2005; 25: 297-310
84. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF-1alpha is essential for myeloid cellmediated inflammation. Cell. 2003; 112: 645-657
85. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000; 14: 1983-1991
86. Arnold F, West D, Kumar S. Wound healing: the effect of macrophage and tumour derived angiogenesis factors on skin graft vascularization. Br J Exp Pathol. 1987; 68: 569-574
87. Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR. The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. 2004; 50: 291-296
88. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008; 51: 1258-1265
89. Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 2001; 61: 795-798
90. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. OncologiSt 2004; 9(suppl 5): 4-9
91. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch. 2005; 450: 363-371
92. Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life. 2001; 52: 49-53
93. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science. 1988; 242: 1412-1415
94. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O 2 tension. Proc Natl Acad Sci USA. 1995; 92: 5510-5514
95. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-Alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood. 1999; 94: 1561-1567
96. Albina JE, Mastrofrancesco B, Vessella JA, Louis CA, Henry WL J., Reichner JS. HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-Alpha. Am J Physiol Cell Physiol. 2001; 281: C1971-C1977
97. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and nonhypoxic activators. Int J Biochem Cell Biol. 2005; 37: 535-540
98. Kong T, Eltzschig HK, Karhausen J, Colgan SP, Shelley CS. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc Natl Acad Sci USA. 2004; 101: 10440-10445
99. Ioannou M, Sourli F, Mylonis I, Barbanis S, Papamichali R, Kouvaras E, Zafiriou E, Siomou P, Klimi E, Simos G, Roussaki-Schulze AV, Koukoulis G. Increased HIF-1 alpha immunostaining in psoriasis compared to psoriasiform dermatitides. J Cutan Pathol. 2009; 36: 1255-1261
100. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007; 56: 901-911
101. Cao R, Jensen LD, Soll I, Hauptmann G, Cao Y. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One. 2008; 3: e2748
102. Del Rey MJ, Izquierdo E, Usategui A, Gonzalo E, Blanco FJ, Acquadro F, Pablos JL. The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum. 2010; 62: 3584-3594
103. Akhavani MA, Madden L, Buysschaert I, Sivakumar B, Kang N, Paleolog EM. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther. 2009; 11: R64
104. Huerta-Yepez S, Baay-Guzman GJ, Bebenek IG, Hernandez-Pando R, Vega MI, Chi L, Riedl M, Diaz-Sanchez D, Kleerup E, Tashkin DP, Gonzalez FJ, Bonavida B, Zeidler M, Hankinson O. Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy. 2011; 66: 909-918
105. Kim SR, Lee KS, Park HS, Park SJ, Min KH, Moon H, Puri KD, Lee YC. HIF-1alpha inhibition ameliorates an allergic airway disease via VEGF suppression in bronchial epithelium. Eur J Immunol. 2010; 40: 2858-2869
106. Guo J, Lu W, Shimoda LA, Semenza GL, Georas SN. Enhanced interferon-gamma gene expression in T Cells and reduced ovalbumin-dependent lung eosinophilia in hypoxia-inducible factor-1-Alphadeficient mice. Int Arch Allergy Immunol. 2009; 149: 98-102
107. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol. 2009; 9: 609-617
108. Sumbayev VV, Nicholas SA. Hypoxia-inducible factor 1 as one of the 'signaling drivers' of Toll-like receptor-dependent and allergic inflammation. Arch Immunol Ther Exp (Warsz) 2010; 58: 287-294
109. Crotty Alexander LE, Akong-Moore K, Feldstein S, Johansson P, Nguyen A, McEachern EK, Nicatia S, Cowburn AS, Olson J, Cho JY, Isaacs H Jr, Johnson RS, Broide DH, Nizet V. Myeloid cell HIF-1alpha regulates asthma airway resistance and eosinophil function. J Mol Med (Berl) 2013; 91: 637-644
110. Lee SY, Kwon S, Kim KH, Moon HS, Song JS, Park SH, Kim YK. Expression of vascular endothelial growth factor and hypoxia-inducible factor in the airway of asthmatic patients. Ann Allergy Asthma Immunol. 2006; 97: 794-799
111. Early SB, Hise K, Han JK, Borish L, and Steinke JW. Hypoxia stimulates inflammatory and fibrotic responses from nasal-polyp derived fibroblasts. Laryngoscope. 2007; 117: 511-515
112. Hsu YC, Kuo WR, Chen YY, Tai CF, Tsai CJ, Wang LF. Increased expression of hypoxia-inducible factor 1alpha in the nasal polyps. Am J Otolaryngol. 2007; 28: 379-383
113. Lin SK, Shun CT, Kok SH, Wang CC, Hsiao TY, Liu CM. Hypoxia-stimulated vascular endothelial growth factor production in human nasal polyp fibroblasts: effect of epigallocatechin-3-gallate on hypoxia-inducible factor-1 alpha synthesis. Arch Otolaryngol Head Neck Surg. 2008; 134: 522-527
114. Chien CY, Tai CF, Ho KY, Kuo WR, Chai CY, Hsu YC, Wang LF. Expression of hypoxia-inducible factor 1alpha in the nasal polyps by real-Time RT-PCR and immunohistochemistry. Otolaryngol Head Neck Surg. 2008; 139: 206-210.
115. Nissim Ben Efraim AH, Eliashar R, Levi-Schaffer F. Hypoxia modulates human eosinophil function. Clin Mol Allergy. 2010; 8: 10
116. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003; 170: 3369-3376
117. Wong CK, Zhang JP, Lam CW, Ho CY, Hjelm NM. Opposing effects of sodium salicylate and haematopoietic cytokines IL-3, IL-5 and GM-CSF on mitogen-Activated protein kinases and apoptosis of EoL-1 cells. Immunol InveSt 1999; 28: 365-379
118. Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon HU, Moretta L, Colonna M, Levi-Schaffer F: 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol. 2005; 174: 110-118
119. Munitz A, Bachelet I, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 is critically involved in allergic eosinophilic airway inflammation. Am J Respir Crit Care Med. 2007; 175: 911-918
120. Munitz A, Bachelet I, Eliashar R, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood. 2006; 107: 1996-2003
121. Munitz A, Bachelet I, Eliashar R, Khodoun M, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol. 2006; 177: 77-83
122. Nissim Ben Efraim AH, Karra L, Ben-Zimra M, Levi-Schaffer F. The inhibitory receptor CD300a is upregulated by hypoxia and GM-CSF in human peripheral blood eosinophils. Allergy. 2013; 68: 397-401
123. Clark GJ, Ju X, Tate C, Hart DN. The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends Immunol. 2009; 30: 209-217
124. Barrow AD, Astoul E, Floto A, Brooke G, Relou IA, Jennings NS, Smith KG, Ouwehand W, Farndale RW, Alexander DR, Trowsdale J. Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2. J Immunol. 2004; 172: 5838-5842